Warning: count(): Parameter must be an array or an object that implements Countable in /home/hmc/public_html/wp-content/plugins/formcraft3/formcraft-main.php on line 1013
Welcome to Mineralocorticoid Receptor Antagonist (MRA): Class Review and Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY) .Post Activity Assessment
Thank you and congratulations for attending this educational activity. Remember, continuous professional development is key to success and professional excellence.
This test is composed of 5 questions based on the information provided to you during the activity. You will have two attempts to complete this test. The 30 minutes which will allow enough time to search for the correct answers.
You must exceed the passing score (60%) in order to receive your certificate
0 of 3 questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
0 of 3 questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
Spironolactone is a non-selective MRA that has progestational and anti-androgenic adverse effects due to its nonspecific binding to various steroid receptorsCorrectIncorrect
Non-steroidal Mineralocorticoid Receptor Antagonist:CorrectIncorrect
The RECOVERY trial result showed that tocilizumab is an effective treatment for hospitalised COVID-19 patients who have hypoxia and evidence of inflammation (CRP ≥75 mg/L). Treatment with tocilizumab improved survival and the chances of discharge from hospital alive by 28 days,CorrectIncorrect